PERSPECTIVE THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-12-31 was 0.00 shares.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-09-30 was 91.61K shares, a 26.35% increase year-over-year.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 1.82M shares.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 0.00 shares.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 141.30K shares, a 53.64% decline from fiscal 2024.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 304.80K shares, a 84.07% decline from fiscal 2023.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.91M shares.
- PERSPECTIVE THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 125.00K shares, a 87.12% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 141.30K shares 10-K · filed 2026-03-16 | |
| 2024-12-31 | 304.80K shares 10-K/A · filed 2025-03-28 | |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | 1.91M shares 10-K · filed 2024-03-28 |
| 2023-09-30 | 91.61K shares 10-Q · filed 2023-11-14 | 1.91M shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-06-30 | 1.82M shares 10-Q · filed 2023-08-11 | 1.89M shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | 72.50K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-12-31 | 0.00 shares derived: 10-K 6 month − 10-Q 3 month · filed 2024-03-28 | 72.50K shares derived: sum of 4 quarters · filed 2024-03-28 |
| 2022-09-30 | 72.50K shares 10-Q · filed 2023-11-14 | 197.50K shares derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | 0.00 shares 10-Q · filed 2023-08-11 | 125.00K shares 10-K · filed 2024-03-28 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2023-05-15 | 575.00K shares derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | 125.00K shares 10-Q · filed 2022-02-09 | 1.09M shares derived: sum of 4 quarters · filed 2023-05-01 |
| 2021-09-30 | 0.00 shares 10-Q · filed 2022-11-14 | 970.32K shares derived: sum of 4 quarters · filed 2023-05-01 |
| 2021-06-30 | 450.00K shares derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | 970.32K shares 10-KT · filed 2023-05-01 |
| 2021-03-31 | 514.07K shares 10-Q · filed 2022-05-13 | 520.32K shares derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-12-31 | 6.25K shares 10-Q · filed 2022-02-09 | 268.75K shares derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-09-30 | 0.00 shares 10-Q · filed 2021-11-10 | 262.50K shares derived: sum of 4 quarters · filed 2023-05-01 |
| 2020-06-30 | 0.00 shares derived: 10-KT 12 month − 10-Q 9 month · filed 2023-05-01 | 262.50K shares 10-KT · filed 2023-05-01 |
| 2020-03-31 | 262.50K shares 10-Q · filed 2021-05-14 | 312.50K shares derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-12-31 | 0.00 shares 10-Q · filed 2021-02-09 | 56.90K shares derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-09-30 | 0.00 shares 10-Q · filed 2020-11-13 | 56.90K shares derived: sum of 4 quarters · filed 2021-09-27 |
| 2019-06-30 | 50.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-27 | 56.90K shares 10-K · filed 2021-09-27 |
| 2019-03-31 | 6.90K shares 10-Q · filed 2020-05-13 | 6.90K shares derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-12-31 | 0.00 shares 10-Q · filed 2020-02-12 | 0.00 shares derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-09-30 | 0.00 shares 10-Q · filed 2019-11-13 | 82.81K shares derived: sum of 4 quarters · filed 2020-09-25 |
| 2018-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-09-25 | 82.81K shares 10-K · filed 2020-09-25 |
| 2018-03-31 | 0.00 shares 10-Q · filed 2019-05-10 | 82.81K shares derived: sum of 4 quarters · filed 2019-09-27 |
| 2017-12-31 | 82.81K shares 10-Q · filed 2019-02-13 | 82.81K shares derived: sum of 4 quarters · filed 2019-09-27 |
| 2017-09-30 | 0.00 shares 10-Q · filed 2018-11-09 | 6.80K shares derived: sum of 4 quarters · filed 2019-09-27 |
| 2017-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-27 | 6.80K shares 10-K · filed 2019-09-27 |
| 2017-03-31 | 0.00 shares 10-Q · filed 2018-05-04 | 6.80K shares derived: sum of 4 quarters · filed 2018-09-26 |
| 2016-12-31 | 6.80K shares 10-Q · filed 2018-02-09 | 17.07K shares derived: sum of 4 quarters · filed 2018-09-26 |
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-14 | 10.27K shares derived: sum of 4 quarters · filed 2018-09-26 |
| 2016-06-30 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-26 | 56.26K shares 10-K · filed 2018-09-26 |
| 2016-03-31 | 10.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-10 | 129.60K shares derived: sum of 4 quarters · filed 2017-09-28 |
| 2015-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09 | 119.33K shares derived: sum of 4 quarters · filed 2017-09-28 |
| 2015-09-30 | 45.99K shares 10-Q · filed 2016-11-09 | 119.33K shares derived: sum of 4 quarters · filed 2017-09-28 |
| 2015-06-30 | 73.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-09-28 | 206.90K shares 10-K · filed 2017-09-28 |
| 2015-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-10 | 458.21K shares derived: sum of 4 quarters · filed 2016-09-09 |
| 2014-12-31 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2016-02-09 | |
| 2014-09-30 | 133.56K shares 10-Q · filed 2015-11-09 | |
| 2014-06-30 | 324.65K shares derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-09 | 350.98K shares 10-K · filed 2016-09-09 |
| 2013-06-30 | 7.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2015-09-14 | 38.70K shares 10-K · filed 2015-09-14 |
| 2013-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-15 | 46.10K shares derived: sum of 4 quarters · filed 2014-05-15 |
| 2012-12-31 | 13.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2014-02-14 | 46.10K shares derived: sum of 4 quarters · filed 2014-02-14 |
| 2012-09-30 | 18.00K shares 10-Q · filed 2013-11-14 | |
| 2012-06-30 | 14.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2013-09-30 | 19.60K shares 10-K · filed 2013-09-30 |
| 2012-03-31 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2013-05-15 | |
| 2011-06-30 | 75.13K shares 10-K/A · filed 2012-10-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |